430 related articles for article (PubMed ID: 11005845)
1. A structural basis for drug-induced long QT syndrome.
Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
[TBL] [Abstract][Full Text] [Related]
2. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
Chen J; Seebohm G; Sanguinetti MC
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12461-6. PubMed ID: 12209010
[TBL] [Abstract][Full Text] [Related]
3. Open channel block of HERG K(+) channels by vesnarinone.
Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
5. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain.
Sănchez-Chapula JA; Ferrer T; Navarro-Polanco RA; Sanguinetti MC
Mol Pharmacol; 2003 May; 63(5):1051-8. PubMed ID: 12695533
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical features of the HERG channel drug binding site.
Fernandez D; Ghanta A; Kauffman GW; Sanguinetti MC
J Biol Chem; 2004 Mar; 279(11):10120-7. PubMed ID: 14699101
[TBL] [Abstract][Full Text] [Related]
7. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
Scholz EP; Zitron E; Kiesecker C; Lueck S; Kathöfer S; Thomas D; Weretka S; Peth S; Kreye VA; Schoels W; Katus HA; Kiehn J; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):404-14. PubMed ID: 14557918
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
9. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
[TBL] [Abstract][Full Text] [Related]
12. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
Scherer CR; Lerche C; Decher N; Dennis AT; Maier P; Ficker E; Busch AE; Wollnik B; Steinmeyer K
Br J Pharmacol; 2002 Nov; 137(6):892-900. PubMed ID: 12411421
[TBL] [Abstract][Full Text] [Related]
13. Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels.
Herzberg IM; Trudeau MC; Robertson GA
J Physiol; 1998 Aug; 511 ( Pt 1)(Pt 1):3-14. PubMed ID: 9679158
[TBL] [Abstract][Full Text] [Related]
14. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
Milnes JT; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
Br J Pharmacol; 2003 Jul; 139(5):887-98. PubMed ID: 12839862
[TBL] [Abstract][Full Text] [Related]
15. Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome.
Satler CA; Walsh EP; Vesely MR; Plummer MH; Ginsburg GS; Jacob HJ
Am J Med Genet; 1996 Oct; 65(1):27-35. PubMed ID: 8914737
[TBL] [Abstract][Full Text] [Related]
16. I(Kr): the hERG channel.
Tseng GN
J Mol Cell Cardiol; 2001 May; 33(5):835-49. PubMed ID: 11343409
[TBL] [Abstract][Full Text] [Related]
17. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Sanguinetti MC; Mitcheson JS
Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E; Jarolimek W; Brown AM
Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC; Friederich P
Anesthesiology; 2007 Mar; 106(3):523-31. PubMed ID: 17325511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
